ReutersReuters

Datroway Continues To Show Promising Tumor Responses As Part Of Combination Regimens In Patients With Early And Advanced Non-Small Cell Lung Cancer

RefinitivMenos de 1 minuto de lectura

Daiichi Sankyo Co Ltd 4568:

  • DATROWAY® CONTINUES TO SHOW PROMISING TUMOR RESPONSES AS PART OF COMBINATION REGIMENS IN PATIENTS WITH EARLY AND ADVANCED NON-SMALL CELL LUNG CANCER

  • DAIICHI SANKYO CO LTD - PHASE 2 RESULTS SHOW POTENTIAL FOR DATROWAY PLUS DURVALUMAB

Inicie sesión o cree una cuenta gratuita y permanente para leer esta noticia